Allergy/Immunology
RSSArticles
-
Researchers Address HIV Treatment Gap Among Underserved Population
There are effective medications, but social determinants of health can dictate adherence.
-
COVID-19 and Headache
Headache is a common feature of acute COVID-19 infection, as well as a long-standing feature of “long COVID” after recovery from the acute infection. Treatment is symptomatic, based on the characteristics of the headache syndrome.
-
Smallpox and Monkeypox Vaccine, Live, Non-Replicating (Jynneos)
Jynneos can be administered to prevent smallpox and monkeypox in adults age 18 years and older who are at high risk for contracting the infections.
-
COVID-19 Rebound
Symptomatic and virologic recrudescence after treatment of patients with COVID-19 with Paxlovid occurs in a tiny percentage of patients and generally is mild and self-limited.
-
Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373)
Novavax is authorized to be administered to patients age 18 years and older for active immunization to prevent COVID-19 caused by SARS-CoV-2.
-
COVID-19 Pre-Exposure Prophylaxis
The combination of tixagevimab and cilgavimab (Evusheld) was demonstrated to be effective in the prevention of symptomatic COVID-19, but much remains to be learned as SARS-CoV-2 continues to evolve.
-
Who Can Receive the Non-mRNA COVID-19 Vaccine Now?
The FDA recently limited the use of the Janssen COVID-19 vaccine.
-
Ethical Precision Medicine Requires Relying on Scientific Evidence, Safeguarding Information
American College of Physicians offers guidance as genome sequencing technology progresses quickly.
-
Two-Dose Novavax Added to List of U.S. COVID-19 Vaccines
The FDA issued an emergency use authorization for the fourth vaccine.
-
Long COVID Patients Report Symptoms 15 Months Later
Brain fog, dizziness, and more side effects can linger for many months after initial SARS-CoV-2 infection.